

Concentration of perfluorinated compounds and cotinine in human fetal organs, placenta, and maternal plasma

**3 Linn Salto Mamsen^{1*}, Bo A.G. Jönsson², Christian H. Lindh², Rasmus H. Olesen³, Agnete Larsen³, Erik
4 Ernst⁴, Thomas W. Kelsey⁵, Claus Yding Andersen¹**

⁶ ¹Laboratory of Reproductive Biology, Section 5712, The Juliane Marie Centre for Women, Children and
⁷ Reproduction, University Hospital of Copenhagen, University of Copenhagen, Rigshospitalet, 2100
⁸ Copenhagen, Denmark. Yding@rh.regionh.dk

9 ²Division of Occupational and Environmental Medicine, Department of Laboratory Medicine, Lund
10 University, 223 61 Lund, Sweden. Christian.lindh@med.lu.se

¹¹ ³Department of Biomedicine - Pharmacology, Aarhus University, 8000 Aarhus C, Denmark. AI@biomed.au.dk

¹² Department of Obstetrics and Gynaecology, University Hospital of Aarhus, Skejby Sygehus, 8000 Aarhus,
¹³ Denmark. Erik.ernst@skejby.rm.dk

¹⁴ ⁵School of Computer Science, University of St. Andrews, KY16 9SX St. Andrews, United Kingdom. twk@st-andrews.ac.uk

17 *Correspondence address: Blegdamsvej 9, 2100 Copenhagen, Denmark, Tel: +45 35455830; Fax: +45-

17 *Correspondence address: Blegdamsvej 9, 2100 Copenhagen, Denmark, Tel: +45 35455830; Fax: +45-
18 35455824; E-mail: linn.salto.mamsen@regionh.dk

19 Running title: PFASs in maternal plasma, placenta, and fetuses

20

21 Financial interest declaration

22 The financial supporters had no role in the study design, collection and analysis of data, data interpretation
23 or in writing the report. The corresponding author had full access to all data presented in the study and had
24 the final responsibility for the decision to submit this paper for publication.

25 Conflict of interest

26 None declared.

27

28 **ABSTRACT**

29 **Background:** Perfluoroalkyl substances (PFASs) have been frequently used for many years in industrial and
30 consumer products. Maternal cigarette smoking may be associated with maternal PFAS levels. Further,
31 prenatal exposure to PFASs is suggested impact on human fetal development and may have long-term
32 adverse health effects later in life. Fetal exposure has previously been estimated from umbilical cord
33 plasma, but the actual concentration in fetal organs has never been measured.

34 **Objectives:** Concentrations of 5 PFASs and cotinine – the primary metabolite of nicotine – was measured in
35 human fetuses, placentas, and maternal plasma to evaluate to what extend these compounds were
36 transferred from mother to fetus, and to see if PFAS concentration was associated with maternal cigarette
37 smoking.

38 **Methods:** A total of 39 Danish women who underwent legal termination of pregnancy before gestational
39 week 12 were included; 24 maternal blood samples were obtained together with 34 placenta tissue and
40 108 fetal organs. PFASs and cotinine were assayed by liquid chromatography/ triple quadrupole mass
41 spectrometry.

42 **Results:** In fetal organs perfluorooctanesulfonic acid (PFOS) 0.6 ng/g, perfluorooctanoic acid (PFOA) 0.2
43 ng/g, perfluorononanoic acid (PFNA) 0.1 ng/g, perfluoroundecanoic acid (PFUnDa) 0.1 ng/g, and
44 perfluorodecanoic acid (PFDA) 0.1 ng/g was detected. In fetal organs the mean concentrations of PFOS,
45 PFOA, PFNA, and PFUnDA were reduced to 5–13% of the concentration found in maternal plasma; PFDA
46 was reduced to 27%. A significant positive correlation was found between fetal age and fetal levels for all
47 five PFASs evaluated. A significant positive correlation was also found between fetal age and fetal cotinine
48 levels. A significant negative correlation was found between maternal BMI and maternal plasma PFNA and
49 and PFUnDA concentrations. Smokers presented with 99 ng/g cotinine in plasma, 108 ng/g in placenta, and
50 61 ng/g in fetal organs, non-smokers showed cotinine levels below 0.2 ng/g in all evaluated compartments.
51 No correlation between maternal cotinine levels and PFASs levels were found.

52 **Conclusions:** PFASs were transferred from mother to fetus, however with a markedly differently efficacy.
53 The concentrations of PFOS, PFOA, PFNA, and PFUnDA in fetal organs were 7–20 times lower than
54 maternal levels, whereas PFDA was four times lower. Furthermore, a significant correlation between fetal
55 age and all evaluated PFASs was found. The health-compromising levels of these substances in fetal life are
56 unknown.

57 **KEYWORDS:** Prenatal exposure, perfluorinated compounds, cigarette smoke, maternal plasma, placenta

58

59 **ABBREVIATIONS:** BMI, body mass index; EDTA, ethylenediamine tetraacetic acid; IS, internal standard; LOD,
60 limit of detection; pc, post conception; PCR, polymerase chain reaction; PFAS, perfluoroalkyl substance;

61 PFASs, perfluoroalkyl substances; PFDA, perfluorodecanoic acid; PFNA, perfluorononanoic acid; PFOA,
62 perfluorooctanoate; PFOS, perfluorooctanesulfonate; PFUnDA, perfluoroundecanoic acid; TDI, tolerable
63 daily intake.

64 **ACKNOWLEDGEMENTS /FUNDING:**

65 We thank The Research Pools of Rigshospitalet and EU interregional project ReproUnion for founding this
66 study.

67

68 **Introduction**

69 Perfluoroalkyl substances (PFASs) are slowly degradable pollutants and belong to the group of water- and
70 grease resistant fluorosurfactants used for many industrial and consumer applications, like outdoor clothes,
71 non-stick cookware, food packaging, electronics, stain-resistant carpets and in fire-fighting foams (Key *et*
72 *al.*, 1997; Jensen and Leffers, 2008; De Solla *et al.*, 2012). The PFASs include perfluorooctanesulfonic acid
73 (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA) and
74 perfluoroundecanoic acid (PFUnDA), all of which suspected to have negative impact on fetal growth and
75 development and may disturb the endocrine system (de Cock *et al.*, 2014; Johnson *et al.*, 2014; Bach *et al.*,
76 2015). Prenatal exposure to PFOS and PFOA has been associated with an increased risk of congenital
77 cerebral palsy in Danish boys (Liew *et al.*, 2014) and maternal exposure to PFNA and PFDA has been
78 associated with increased risk of pregnancy lost (Jensen *et al.*, 2015). In rodents, prenatal exposure to high
79 doses of PFOS and PFOA reduced postnatal survival and birth weight, and disturbed lactation and growth of
80 the pups (Lau *et al.*, 2004; Olsen *et al.*, 2009) and both pre and postnatal PFASs exposure have been
81 associated with hypothyroidism and significant decreased T4 levels in pups (Yu *et al.*, 2009).

82 PFASs, and particularly PFOA and PFNA, have been shown to induce synthesis of the estrogen-responsive
83 biomarker protein vitellogenin leading to an estrogen-like activity *in vivo* in rainbow trout (Benninghoff *et*
84 *al.*, 2011).

85

86 Notably, PFASs half-life in rats is as short as a few days (Kudo *et al.*, 2002), compared to 200 days in the
87 cynomolgus monkey (Seacat *et al.*, 2002), and 2.5–4.5 years in humans (Olsen *et al.*, 2007; Zhang *et al.*,
88 2013), suggesting a large difference in the elimination kinetics between species, and therefore animal
89 models may only reflect the human situation to a limited extent.

90

91 Human fetal exposure has been estimated from levels measured in maternal circulation and umbilical cord
92 blood in newborns. Prenatal exposure to PFOA has been associated with decreased birth weight in a dose
93 dependent manner (Johnson *et al.*, 2014; Lauritzen *et al.*, 2017). An association between PFOS exposure
94 and birth weight has also been suggested, but reported results are conflicting (Bach *et al.*, 2015) whereas
95 prenatal PFOS and PFOA exposure has been suggested to negatively affect thyroid function. In new-born
96 boys, T4 levels decreased with increasing prenatal exposure to PFOS and PFOA. Surprisingly, the same study
97 found the opposite effect in girls where the T4 level increased with increasing prenatal exposure to PFOA
98 (de Cock *et al.*, 2014). In human breast cancer cells, PFOA are suggested to be cytotoxic and to exert an
99 estrogen effect, though an anti-estrogen effect was found when cells were co-exposed to estradiol (Henry
100 and Fair, 2013). Information on the actual concentration of PFASs in human tissues is limited, but a few

101 reports do exist (Olsen *et al.*, 2003a; Maestri *et al.*, 2006; Kärrman *et al.*, 2010; Pérez *et al.*, 2013). Lung
102 tissue is suggested to accumulate the highest concentration of PFASs in general, though PFOS and PFOA
103 tend to accumulate with highest prevalence in liver and bone structures, respectively (Pérez *et al.*, 2013). In
104 liver, PFOS was detected in higher concentrations than PFOA (Maestri *et al.*, 2006; Kärrman *et al.*, 2010;
105 Pérez *et al.*, 2013). In human liver, PFOA has been detected in higher levels than PFNA and PFDA in one
106 report (Pérez *et al.*, 2013) and in similar levels in another (Kärrman *et al.*, 2010). PFASs were found in all
107 human tissues (Pérez *et al.*, 2013). The tissue concentrations in human fetal organs are currently not
108 available.

109

110 Maternal cigarette smoking, together with other lifestyle parameters, may impact maternal PFAS levels
111 (Lauritzen *et al.*, 2016), why the present study included maternal smoking and other lifestyle factors in
112 order to evaluate if maternal lifestyle affected maternal and fetal PFAS levels. Cotinine is the primary
113 metabolite of nicotine and is a valid biomarker used to discriminate smokers from non-smokers (Benowitz
114 *et al.*, 2003). The adverse effects that maternal smoking has on the unborn child is well-known and widely
115 described (Mund *et al.*, 2013). Plasma cotinine concentrations in newborns have been reported to be
116 approximately 60 ng/mL in children of heavy smokers, 30 ng/mL in children from moderate smokers, and 3
117 ng/mL in children from non-smokers (Ivorra *et al.*, 2014). The actual concentrations in human fetuses have
118 not previously been measured.

119

120 The present study is, to our knowledge, the first to measure the actual concentrations of PFASs and
121 cotinine in human first trimester fetuses. These findings provide (i) important new knowledge on the
122 perfusion of PFASs and cotinine from mother over the early placenta barrier to fetal circulation and organs,
123 and (ii) evaluate if fetal age is associated with fetal PFASs levels indicating a fetal accumulation over time
124 and (III) whether maternal cigarette smoking affects PFASs accumulation in mother and fetus.

125 **Materials and Methods**

126 *2.1. Participating women*

127 The participants were healthy women aged 18-46 years (mean \pm SEM, 26.4 \pm 1.1), who had decided to
128 terminate pregnancy for other reasons than fetal abnormality. Exclusion criteria: age under 18 years,
129 chronic diseases, dependency on an interpreter. The project was approved by the Research Ethics
130 Committees of the Regional Capital (H-KF 01 258206); all participants received oral and written information
131 and gave their informed consent. The participants answered a detailed questionnaire concerning lifestyle
132 habits during pregnancy, including smoking and drinking habits.

133 *2.2. Human fetal tissues and maternal blood samples*

134 Legal abortions were performed at the Department of Obstetrics and Gynaecology, University Hospital
135 Skejby, Denmark and at Department of Obstetrics and Gynaecology, Regional Hospital Randers, Denmark,
136 in collaboration with the Laboratory of Reproductive Biology, Rigshospitalet, Denmark. All fetuses were
137 morphologically normal. Within one hour after the surgical procedure the fetal organs and placenta tissue
138 were isolated, washed in sterile saline snap frozen on dry ice, and stored at -80 °C until analysis. Fetal
139 organs and placenta tissue processed for freezing more than one hour after collection were not included in
140 the present study. Fetal age was measured by crown-rump lengths via ultrasound in connection with the
141 surgical procedure. Gestational age was converted to age post conception by subtracting two weeks.
142 Maternal blood samples were obtained in connection with anaesthesia prior to surgery, collected in
143 ethylenediamine tetraacetic acid (EDTA) tubes, and kept on ice until centrifugation (4.000g for 15 min) to
144 isolate plasma. Plasma was aliquoted to 200 µl microinserts in 1.5 mL vials (Skandinaviska GenTec, Västra
145 Frölunda, Sweeden) and stored at -20°C until analysis.

146

147 *2.3. Tissue processing*

148 Fetal- and placenta samples were homogenized in 70% acetonitril solution containing isotopically labelled
149 cotinine and PFASs as internal standards (IS) with three parts solution and one part tissue. Homogenization
150 was performed using a TissueLyser (Qiagen, Copenhagen, Denmark) with a 0.5 mm. stainless steel bead for
151 one min. at 15 Hz, thereafter shaken at room temperature (RT) for 30 min. followed by 1600 g.
152 centrifugation. The supernatant was transferred to 100 µl inserts fitted for 1.5 mL vials. The samples were
153 transported at -20°C to the Division of Occupational and Environmental Medicine for further analysis.

154

155 *2.4. Analysis of PFASs and cotinine*

156 The analyses of PFOS, PFOA, PFNA, PFUnDa, PFDA and cotinine in the plasma, placenta and fetal tissues
157 samples were performed by LC/MS/MS (QTRAP 5500; AB Sciex, Foster City, CA, USA coupled to a liquid
158 chromatography system (UFLCXR, Shimadzu Corporation, Kyoto, Japan) according to procedures set out by
159 Lindh et al. (Lindh *et al.*, 2012). Plasma samples for calibration standards were obtained from healthy
160 volunteers at the laboratory in Lund. Plasma was also used as a proxy matrix for the tissue samples. The
161 levels were quantified and samples with low amounts of all compounds were selected for the calibration
162 standards. Calibration standards were prepared by adding a standard solution containing all analyzed
163 compounds. Concentrations were determined by peak area ratios between the analytes and the IS. The
164 levels of all compounds in the pooled serum used for preparation of standards were quantified in each
165 batch, and the calibration standards were corrected for the concentration found in this sample. Also, all

166 values were corrected for the chemical blank. The limit of detection (LOD) was determined as the
167 concentration corresponding to three times the standard deviation of the ratio of the peak at the same
168 retention time as the analyzed compounds, and the corresponding IS determined in the chemical blank
169 samples. Tissue extraction time was tested for 5, 15, 30, 45 min. It was found that after 30 min. no
170 additional chemicals were extracted from the tissue, and a 30 min. extraction time was subsequently used
171 for all samples included in the present study. To make sure the study set-up was not contaminated with
172 other chemicals, blank samples (IS solution) were included for all batches of tissue prepared and treated
173 exactly the same way as the actual samples (see section 2.3.). No chemical contamination detected.
174 Further quality-assurance analysis was not made due to limited fetal material.

175

176 *2.6. Statistical methods*

177 All statistical analyses were performed using GraphPad Prism 6.07 program (GraphPad Software, Inc., CA,
178 USA) and RStudio program (RStudio software, Boston, Massachusetts, USA). Significance level was defined
179 as a probability lower than 0.05 ($p=0.05$). An unpaired non-parametric *t*-test was used to compare PFA
180 levels in plasma from smoking versus non-smoking women. Spearman's rank test was performed to test for
181 correlation between PFASs and cotinine, PFASs and fetal age, PFASs and lifestyle parameters. Additionally a
182 linear regression model was used to test the potential correlations between the PFAS levels and lifestyle
183 parameters, maternal and fetal ages. A pairwise correlation model was used to test if the lifestyle
184 parameters correlated.

185

186 *2.7. Limitations*

187 A direct measurement of PFAS levels in fetal blood cannot be performed as it is not possible to obtain blood
188 samples from fetuses at these early developmental stages. Fetal organs were used instead and their PFASs
189 content compared to levels present in maternal circulation. Previously, PFOS have been measured in serum
190 and liver tissue and a mean liver to serum ratio was reported to 1.3 to 1 in adults (34–70 years) (Olsen *et*
191 *al.*, 2003b). However, PFOS has been found in the higher concentration in liver compared to other organs
192 (Pérez *et al.*, 2013). Taken together, these finding suggest similar concentrations in serum and tissues and it
193 is unlikely that the comparison between maternal plasma (mL) and fetal organs (g) significantly affects the
194 results. The number of fetal organs obtained from the same fetus was limited why a potential organ
195 specific accumulation cannot be evaluated.

196

197 **Results**

198 Thirty-nine women were included in this study and a total of 34 placenta samples, 108 fetal organs and 24
199 blood samples were obtained from the participants (for detailed distribution see Fig. 1). The 108 organs
200 were obtained from a total of 36 fetuses aged 37–68 days pc (mean \pm SEM, 52 \pm 1.3)(Fig. 1).

201

202 *3.1. Cotinine concentrations in plasma, placenta, and fetal organs*

203 A plasma cut-off value of 3 ng/mL was used to discriminate between smokers and non-smokers (Benowitz
204 *et al.*, 2009). Three participants reported themselves as non-smokers but presented with cotinine levels
205 above the cut-off value. They were grouped as smokers and their questionnaire excluded from analysis.
206 Women who smoked had significantly higher levels cotinine levels in maternal plasma, placenta, and fetal
207 organs compared to non-smokers ($p<0.001$, $p<0.0001$, $p<0.0001$, respectively). Mean plasma levels (\pm SEM)
208 in smokers were 99.3 ng/g \pm 26.9, range: 6.2–326.1 ng/g, and in non-smokers 0.2 ng/g \pm 0.1; range: 0–1.1
209 ng/g (Table 2). Cotinine concentration in smoke-exposed placentas was 107.8 ng/g \pm 22.3; 3.8–374.7 (mean
210 \pm SEM; range) and in non-exposed placentas 0.4 ng/g \pm 0.1; 0.0–1.8 (mean \pm SEM; range) (Table 2). Cotinine
211 levels in smoke-exposed and non-exposed fetal organs were 61.1 ng/g \pm 9.2; 1.1–336 (mean \pm SEM; range)
212 ($p<0.0001$) and 0.4 ng/g (range: 0–2.6), respectively (Table 2). Cotinine was detected in all different fetal
213 organs exposed to cigarette smoke (Fig. 2). Cotinine was hardly detectable in the placentas and fetal organs
214 of non-smokers (Fig. 2). In the group who smoked, a significant positive correlation was found between
215 fetal age and the fetal to maternal cotinine ratio ($p=0.0168$) (Fig 3.). There were no association between the
216 number of cigarettes smoked and the cotinine concentration in fetal tissue ($p>0.1$) (data not shown).

217 Maternal plasma, placenta and fetal organs from the same women were available in 21 cases. From each
218 woman, the mean cotinine concentration (ng/g) in fetal organs was calculated and the overall mean
219 presented (Table 3). The percentage was calculated as concentrations in fetal organs and placenta
220 respectively in relation to the corresponding maternal plasma (100%) (Table 3).

221 *3.2. PFASs concentrations in maternal plasma, placenta, and fetal organs*

222 Significant positive correlations between fetal age and the fetal to maternal ratio of all five PFASs were
223 found: PFOS $p=0.0008$, 95% CI [0.33–0.86]; PFOA $p=0.0246$, 95% CI [0.06–0.77], PFNA $p=0.0106$, 95% CI
224 [0.13–0.80]; PFUnDA $p=0.0197$, 95% CI [0.08–0.77]; PFDA $p=0.0390$, 95% CI [0.01–0.75] (Fig. 3). Further,
225 significantly linear correlations were found for PFOS ($p=0.0011$), PFNA ($p=0.0243$), and PFUnDA ($p=0.0467$)
226 (Fig. 3).

227 The concentration of PFASs in maternal plasma, placenta, and fetal organs was presented in Table 2. The
228 PFAS levels in plasma from women who smoked were higher compared to women who did not smoke,

229 though not at a significant level for any of the PFASs. All five measured PFASs were present in the evaluated
230 fetal organs. No association between maternal plasma cotinine levels and plasma PFASs was found ($p>0.1$).
231

232 Maternal plasma, placenta tissue and fetal organs were available for each of 21 cases. PFASs in placenta
233 and fetal organs were greatly reduced compared to maternal plasma. The relative concentrations of PFOS,
234 PFOA, PFNA, and PFUnDA in placentas were 11–15% of the concentration found in maternal plasma, and
235 were further reduced to 5–13% in fetal organs (Table 3). PFDA was detected in relatively higher
236 concentration in placenta (43%) and fetal organs (27%) compared the other PFASs (Table 3). PFOS in
237 maternal plasma was significantly higher compared to the other PFASs measured. Interestingly, PFOS was
238 detected in the lowest relative concentration in fetal organs (5%) (Table 3).

239

240 3.3. Correlation between lifestyle and PFAS levels

241 Maternal characteristic and life-style habits were presented in Table 1. The concentrations of PFNA and
242 PFUnDA showed a significant negative association with BMI ($p=0.0391$; $p=0.0085$, respectively) (Fig. 4),
243 while there was no significant association between BMI and fetal PFASs levels ($p>0.1$) and between PFASs
244 and maternal cigarette smoking, maternal age, or rual/urban residence ($P>0.1$).
245

246 Further, a positive correlation (over 50%) was found between first-hand smoking and second-hand smoking
247 ($r=0.65$, $p<0.0001$), second-hand smoke smoking also correlated positively with fathers smoking habits
248 ($r=0.50$, $p=0.004$) (Supp. Table 1). Alcohol consumption correlated positively with soft drink consumption
249 ($r=0.57$, $p=0.0002$) (Supp. Table 1). Use of over the counter medication correlated positively with use of
250 prescription medicine ($r=0.56$, $p=0.0003$) (Supp. Table 1). There was no significant correlation between any
251 other pairs of measured parameters (Supp. Table 1).
252

253 4. Discussion

254 These data demonstrate that PFASs and cotinine are transferred from mother to fetus during the first
255 trimester of pregnancy and that fetal PFASs levels increase with fetal age, suggesting that these substances
256 may accumulate in the fetus during gestation. All five evaluated PFASs were significantly higher in maternal
257 circulation as compared to fetal levels. Further a negative correlation between maternal BMI and plasma
258 concentrations of PFNA and PFUnDA were found supporting previous reports (Lauritzen *et al.*, 2016).
259 Collectively, these data provide information on the exact PFAS concentrations present in fetal organs,
260 placenta, and maternal plasma during first trimester of pregnancy together with the transfer rate from
261 mother to fetus.

262 *4.1. Fetal age correlated positively with fetal concentrations of all five PFASs*

263 Fetal age correlated positively with fetal concentrations of all five PFASs evaluated, suggesting that these
264 compounds accumulate in the fetal tissues and may continue to increase during pregnancy. It has been
265 shown that phthalates and PFOS accumulate in the human amniotic fluid during the second trimester at
266 almost 10% per gestational week (Jensen *et al.*, 2012), supporting the present findings. Given that the
267 development of keratinized epidermal skin is first seen in human fetuses from week 22 pc (Hardman *et al.*,
268 1999), the fetal skin will prior to this age be permeable and chemicals from the amniotic fluid may be
269 absorbed by this route. Hence in early pregnancy the fetus may be exposed to PFASs from both placental
270 blood and from the amniotic fluid.

271

272 *4.2. PFASs in human fetal organs in relation to maternal levels*

273 The five PFASs were detected in all the different fetal organs evaluated indicating that fetuses are
274 systemically exposed to these compounds. Although the majority of the organogenesis are completed
275 around weeks six to eight (Zhou *et al.*, 2012), the organs are still at an early immature stage, and an
276 organ-specific accumulation is not expected at this early age. In adults, PFOA and PFOS accumulate in liver
277 and bone structures (Pérez *et al.*, 2013), further all the five PFASs evaluated in the present study have been
278 detected in adult liver tissue (Kärrman *et al.*, 2010) suggesting that the tissue accumulation the present
279 study find in fetal life continues in adulthood.

280 The concentrations of PFOS, PFOA, PFNA, and PFUnDA in placenta were reduced to 11–15% of the
281 concentrations found in the maternal circulation. These levels were further attenuated across the placenta
282 to the fetal organs, to a level of 5–13% of the concentration found in maternal plasmas, indicating that the
283 fetal exposure to these compounds was 7–20 times lower than the maternal levels. Of the PFASs
284 examined, PFDA were found in the lowest concentrations in maternal plasma, but showed the relative
285 highest concentration in both placenta (43%) and fetal tissues (27%) as compared to maternal plasma.
286 Although the assay of measurement is close to the detection limit, these values are within the standard
287 curve and are considered valid. These data suggest that PFASs accumulate in fetal tissue with different
288 efficiency. The differences in in fetal uptake may be due to different placental clearance or fetal age.

289 Previously, fetal concentrations of PFOS, PFOA, and PFNA have been estimated from the concentrations
290 measured in the umbilical cord blood (Monroy *et al.*, 2008; de Cock *et al.*, 2014; Manzano-Salgado *et al.*,
291 2015). Our results help qualify estimations of fetal exposure by providing actual measured levels. The
292 present study detected actual fetal concentration of PFASs to be 3–12 times lower than the previous
293 estimated from umbilical cords, which may either reflect that fetal PFAS levels increase during gestation

294 (the present study find a significantly positive correlation between PFASs and fetal age), or indicate that the
295 actual fetal exposure may be less than previously anticipated.

296 *4.3. PFAS levels in maternal plasma*

297 In maternal plasma, PFOS were present in the highest concentration of all PFASs measured followed by
298 PFOA. The lowest concentrations were found in PFNA, PFUnDa, and PFDA, respectively. These findings
299 were reflected in the levels measured in the fetal organs, where PFOS and PFOA also were preset in highest
300 concentrations followed by PFNA, PFUnDa, and PFDA. The maternal PFAS levels support previous
301 measurements from pregnant women (Monroy *et al.*, 2008; Okada *et al.*, 2013, 2014; Cho *et al.*, 2015;
302 Manzano-Salgado *et al.*, 2015; Papadopoulou *et al.*, 2015; Callan *et al.*, 2016; Wang *et al.*, 2016) except for
303 PFUnDA, which has been detected both in higher and lower concentrations (Okada *et al.*, 2013; Callan *et*
304 *al.*, 2016; Wang *et al.*, 2016). Literature is not conclusive with regards to the concentration of PFOS and
305 PFOA in plasma. In a study of 1,400 women, plasma levels of PFOS and PFOA were 4 and 8 times higher
306 than the present study (Fei *et al.*, 2007) whereas Hannsen and colleagues reported 5 and 1.5 times the
307 concentrations of the present study (Hanssen *et al.*, 2010). These differences may be explained by
308 variations in local exposure or by the year in which the samples were taken; during the last decade
309 changing levels of PFASs have been observed (Glynn *et al.*, 2012; Olsen *et al.*, 2012).

310 We found a negative correlation between maternal BMI and the levels of PFNA and PFUnDA in maternal
311 plasma, though the correlation disappeared when compared to fetal levels, suggesting that maternal BMI
312 does not affect the PFNA and PFUnDA levels in the fetus. Maternal cigarette smoking was associated with
313 slightly higher plasma concentration of all five PFASs, but not to a significant level. Conflicting results of the
314 association between maternal cigarette smoking and maternal PFASs levels has been reported (Cho *et al.*,
315 2015; Lauritzen *et al.*, 2016, 2017) and the effect of maternal cigarette smoke may be questionable.
316 Nevertheless, this association was not reflected in placenta and fetal tissues, suggesting that smoking did
317 not affect the levels of PFASs transferred to the fetus. The included women were recruited from both rural
318 and urban areas, and no association was found between where the women were resident and her plasma
319 levels of PFASs, suggesting that exposure to pollutants from urban living does not impact PFAS levels in
320 pregnant women in Denmark.

321 *4.4. Health compromising PFASs levels*

322 Dietary intake has been suggested as the primary source of PFASs exposure (Domingo, 2012; Lauritzen *et*
323 *al.*, 2016) with the largest contribution coming from meat, animal fat, and snacks (Halldorsson *et al.*, 2008).
324 The EFSA CONTAM panel has established a tolerable daily intake (TDI) for PFOS and PFOA of 150 ng/kg/day
325 and 15 µg/kg/day, respectively, based on the lowest non-observed adverse effect level identified in animal

326 exposure studies. The estimated intake of PFOS and PFOA in the present study was 2.7 and 2.1 respectively,
327 which is well below advised TDI. In the Swedish adult population the mean dietary PFAS exposure has been
328 estimated to 0.6–8.5 ng/kg/day (Domingo, 2012), which is also well below the estimated health
329 compromising levels and suggests a minimal health risk at these levels in Scandinavian adults. PFOS and
330 PFOA plasma levels in Swedish women were 10.2 ng/mL and 2.9 ng/mL, respectively (Axmon *et al.*, 2014),
331 which is slightly higher than the maternal plasma levels in the present study. This can be interpreted as
332 neither the Swedish nor the present Danish plasma levels being health compromising in adult women,
333 given that uptake from other sources than diet is insignificant. However, the health compromising levels of
334 PFASs during fetal life is to our knowledge not defined. In pregnant women, plasma PFOA levels above 3.9
335 ng/mL was significantly associated with reduced birth weight (Fei *et al.*, 2007), suggesting that health
336 compromising levels may be lower in fetal life compared to adulthood.

337

338 *4.5. PFASs and lifestyle*

339 We did not find a correlation between the evaluated self-reported lifestyle parameters except between
340 smoking, second-hand smoke and fathers smoking habits, indicating that smokers are more likely to be
341 surrounded by other smokers, and may therefore expose their fetus to more cigarette smoke than their
342 personal cigarette consumption indicates. For all other aspects the lifestyles of the participants were
343 similar. The variation in PFAS concentrations between fetuses could not be explained by the monitored
344 lifestyle parameters: smoking habits, coffee-, tea-, soft drink, soft drink light -consumption, or exercise.
345 Fetal age was found to significantly correlate with PFAS levels in fetal organs and may be the most likely
346 explanation for the variation between fetuses. Differences in placental clearance may also impact on the
347 fetal PFAS levels.

348

349 *4.6. Cotinine concentration in maternal plasma, placenta, and fetal organs*

350 Among smokers, cotinine was detected in significantly higher concentrations in fetal organs compared to
351 PFASs. Cotinine accumulated in placenta and 106% of the concentration found in maternal plasma was
352 detected in placenta. The concentrations in smoke-exposed fetal tissues were reduced to 52% of the
353 concentration found in maternal plasma, indicating that cotinine crosses the placenta relatively easy and
354 reaches the fetal circulation. The mean concentration of cotinine in smoke-exposed fetuses was 61.1 ng/g,
355 which was very close to the concentration previously measured in serum from newborns of heavy smokers
356 (59.1 ng/mL) (Ivorra *et al.*, 2014). This may indicate that even though cotinine reaches the fetus in high
357 concentrations, its clearance is rapid (half-life: 16 hours, total clearance: 48 hours (Benowitz and Jacob,
358 1994)) compared to PFASs (\approx 4 years). Where PFAS tends to accumulate in the fetus, cotinine levels may

359 rather reflect the actual maternal level, which diffuses to the fetus. The highest cotinine concentration was
360 detected in fetal liver, which was close to the same concentration found in the placenta, indicating that
361 cotinine may accumulate in the liver. The lowest cotinine concentration was found in the ribs, likely
362 reflecting that cotinine reaches more perfused organs easier than bone structures.

363

364 **5. Conclusions**

365 In conclusion, the present study provides actual measurements on PFASs and cotinine concentrations in
366 human fetuses, together with comparisons to placenta and maternal plasma samples. Fetal age was
367 positively correlated with all evaluated PFASs, suggesting a fetal accumulation over time. In maternal
368 plasma PFOS levels were more than 4 times higher than PFOA, which were twice as high as PFDA, PFUnDa
369 and PFDA. The PFOS, PFOA, PFNA, and PNUnDA levels were reduced in placenta to 11–15% of the
370 concentration found in maternal plasma, and further reduced to 5–13%. In contrast PFDA, which was
371 present in the lowest concentrations of the evaluated PFASs in maternal plasma, was detected in the
372 relatively highest concentration in the fetus (27%), suggesting that the placenta retains PFASs with different
373 efficiency. These data suggest that fetal PFAS levels increase with fetal age, though the health
374 compromising level of these substances in fetal life is unknown.

375 **Ethical approval**

376 ‘The Scientific Ethical Committee for the Capital Region’ [KF (01) 258206] and [KF (01) 170/99] has given
377 their approval for this study. All participants gave informed consent before taking part and have given
378 written consent to their data can be included in publications.

379 **Authors' roles**

380 L.S.M. was responsible for writing the paper, collected the human fetuses and placenta samples, prepared
381 samples for chemical analysis, did the statistics, and interpreted data. B.A.G.J. and C.H.L. was responsible
382 for the design of the chemical analysis and interpreted data. R.O. did the scanning during the evacuation
383 procedure. A.L. assisted collecting fetal material and placenta samples. E.E. was responsible for the surgical
384 procedure of terminating pregnancies and consulted the participating women in prior to the operation for
385 completion of questionnaires and obtained the blood samples. T.W.K interpreted data, assisted in the
386 statistical correlation analysis, and assisted in writing the paper. C.Y.A. interpreted data, assisted in writing
387 the paper and was responsible for the study design. All authors approved the last version of the
388 manuscript.

389

390 **Reference list**

- 391 Axmon A, Axelsson J, Jakobsson K, Lindh CH, Jönsson BAG. Time trends between 1987 and 2007 for
392 perfluoroalkyl acids in plasma from Swedish women. *Chemosphere* [Internet] 2014;102:61–67.
- 393 Bach CC, Bech BH, Brix N, Nohr EA, Bonde JPE, Henriksen TB. Perfluoroalkyl and polyfluoroalkyl substances
394 and human fetal growth: A systematic review. *Crit Rev Toxicol* [Internet] 2015;45:53–67.
- 395 Benninghoff AD, Bisson WH, Koch DC, Ehresman DJ, Kolluri SK, Williams DE. Estrogen-like activity of
396 perfluoroalkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro.
397 *Toxicol Sci* 2011;120:42–58.
- 398 Benowitz NL, Hukkanen J, Jacob IP. Nicotine Chemistry, Metabolism, Kinetics and Biomarkers. *Handb Exp
399 Pharmacol* [Internet] 2009;192:1–29.
- 400 Benowitz NL, Jacob P. Metabolism of nicotine to cotinine studied by a dual stable isotope method. *Clin
401 Pharmacol Ther* [Internet] 1994;56:483–493.
- 402 Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob 3rd P. Nicotine metabolite ratio as a predictor of
403 cigarette consumption. *Nicotine Tob Res* 2003;5:621–624.
- 404 Callan AC, Rotander A, Thompson K, Heyworth J, Mueller JF, Odland JØ, Hinwood AL. Maternal exposure to
405 perfluoroalkyl acids measured in whole blood and birth outcomes in offspring. *Sci Total Environ*
406 [Internet] 2016;569-570:1107–1113.
- 407 Cho CR, Lam NH, Cho BM, Kannan K, Cho HS. Concentration and correlations of perfluoroalkyl substances in
408 whole blood among subjects from three different geographical areas in Korea. *Sci Total Environ*
409 [Internet] 2015;512-513:397–405. Elsevier B.V.
- 410 Cock M de, Boer MR de, Lamoree M, Legler J, Bor M van de. Prenatal exposure to endocrine disrupting
411 chemicals in relation to thyroid hormone levels in infants - a Dutch prospective cohort study. *Environ
412 Health* [Internet] 2014;13:106. BioMed Central.
- 413 Cui L, Zhou Q-F, Liao C-Y, Fu J-J, Jiang G-B. Studies on the Toxicological Effects of PFOA and PFOS on Rats
414 Using Histological Observation and Chemical Analysis. *Arch Env Contam Toxicol* 2009;56:338–349.
- 415 Domingo JL. Health risks of dietary exposure to perfluorinated compounds. *Environ Int* 2012;40:187–195.
- 416 Fei C, McLaughlin JK, Tarone RE, Olsen J. Perfluorinated Chemicals and Fetal Growth: A Study within the
417 Danish National Birth Cohort. *Environ Health Perspect* [Internet] 2007;115:1677–1682.
- 418 Glynn A, Berger U, Bignert A, Ullah S, Aune M, Lignell S, Darnerud PO. Perfluorinated Alkyl Acids in Blood
419 Serum from Primiparous Women in Sweden: Serial Sampling during Pregnancy and Nursing, And
420 Temporal Trends 1996–2010. *Environ Sci Technol* [Internet] 2012;46:9071–9079.
- 421 Halldorsson TI, Fei C, Olsen J, Lipworth L, McLaughlin JK, Olsen SF. Dietary Predictors of Perfluorinated
422 Chemicals: A Study from the Danish National Birth Cohort. *Environ Sci Technol* [Internet]
423 2008;42:8971–8977. American Chemical Society.
- 424 Hanssen L, Röllin H, Odland JØ, Moe MK, Sandanger TM. Perfluorinated compounds in maternal serum and
425 cord blood from selected areas of South Africa: results of a pilot study. *J Environ Monit* [Internet]
426 2010;12:1355.
- 427 Hardman MJ, Moore L, Ferguson MW, Byrne C. Barrier formation in the human fetus is patterned. *J Invest
428 Dermatol* [Internet] 1999;113:1106–1113. Elsevier Masson SAS.

- 429 Henry ND, Fair P a. Comparison of *in vitro* cytotoxicity, estrogenicity and anti-estrogenicity of triclosan,
430 perfluoroctane sulfonate and perfluorooctanoic acid. *J Appl Toxicol* [Internet] 2013;33:265–272.
- 431 Ivorra C, García-Vicent C, Ponce F, Ortega-Evangelio G, Fernández-Formoso JA, Lurbe E. High cotinine levels
432 are persistent during the first days of life in newborn second hand smokers. *Drug Alcohol Depend*
433 [Internet] 2014;134:275–279.
- 434 Jensen MS, Norgaard-Pedersen B, Toft G, Hougaard DM, Bonde JP, Cohen A, Thulstrup AM, Ivell R, Anand-
435 Ivell R, Lindh CH, et al. Phthalates and perfluoroctanesulfonic acid in human amniotic fluid: Temporal
436 trends and timing of amniocentesis in pregnancy. *Environ Health Perspect* 2012;120:897–903.
- 437 Jensen TK, Andersen LB, Kyhl HB, Nielsen F, Christesen HT, Grandjean P. Association between
438 perfluorinated compound exposure and miscarriage in Danish pregnant women. *PLoS One* [Internet]
439 2015;10:e0123496. Public Library of Science.
- 440 Jensen AA, Leffers H. Emerging endocrine disruptors: perfluoroalkylated substances. *Int J Androl* [Internet]
441 2008;31:161–169.
- 442 Johnson PI, Sutton P, Atchley DS, Koustas E, Lam J, Sen S, Robinson K a, Axelrad D a, Woodruff TJ, Sutton P,
443 et al. The Navigation Guide-Evidence-Based Medicine Meets Environmental Health: Systematic
444 Review of Nonhuman Evidence for PFOA Effects on Fetal Growth. *Environ Health Perspect* [Internet]
445 2014;122:1040–1051.
- 446 Key BD, Howell RD, Criddle CS. Fluorinated Organics in the Biosphere. *Environ Sci Technol* 1997;31:2445–
447 2454.
- 448 Kudo N, Kataura M, Sato Y, Kawashima Y. Sex hormone-regulated renal transport of perfluoroctanoic
449 acid. *Chem Biol Interact* 2002;139:301–316.
- 450 Kärrman A, Domingo JL, Llebaria X, Nadal M, Bigas E, Bavel B Van, Lindström G. Biomonitoring
451 perfluorinated compounds in Catalonia, Spain: concentrations and trends in human liver and milk
452 samples. *Env Sci Pollut Res* 2010;17:750–758.
- 453 Lau C, Butenhoff JL, Rogers JM. The developmental toxicity of perfluoroalkyl acids and their derivatives.
454 *Toxicol Appl Pharmacol* [Internet] 2004;198:231–241.
- 455 Lauritzen HB, Larose TL, Øien T, Odland JØ, Bor M van de, Jacobsen GW, Sandanger TM. Factors Associated
456 with Maternal Serum Levels of Perfluoroalkyl Substances and Organochlorines: A Descriptive Study of
457 Parous Women in Norway and Sweden. *PLoS One* [Internet] 2016;11:e0166127. Public Library of
458 Science.
- 459 Lauritzen HB, Larose TL, Øien T, Sandanger TM, Odland JØ, Bor M Van De. Maternal serum levels of
460 perfluoroalkyl substances and organochlorines and indices of fetal growth: a Scandinavian case–
461 cohort study. *Pediatr Res* 2017;81:33–42.
- 462 Liew Z, Ritz B, Bonefeld-Jorgensen EC, Henriksen TB, Nohr EA, Bech BH, Fei C, Bossi R, Ehrenstein OS von,
463 Streja E, et al. Prenatal Exposure to Perfluoroalkyl Substances and the Risk of Congenital Cerebral
464 Palsy in Children. *Am J Epidemiol* [Internet] 2014;180:574–581. Oxford University Press.
- 465 Lindh CH, Rylander L, Toft G, Axmon A, Rignell-Hydbom A, Giwercman A, Pedersen HS, Góalczyk K, Ludwicki
466 JK, Zvyezday V, et al. Blood serum concentrations of perfluorinated compounds in men from
467 Greenlandic Inuit and European populations. *Chemosphere* [Internet] 2012;88:1269–1275. Elsevier
468 Ltd.
- 469 Maestri L, Negri S, Ferrari M, Ghittori S, Fabris F, Danesino P, Imbriani M. Determination of
470 perfluoroctanoic acid and perfluorooctanesulfonate in human tissues by liquid

- 471 chromatography/single quadrupole mass spectrometry. *Rapid Commun Mass Spectrom* [Internet]
472 2006;20:2728–2734. John Wiley & Sons, Ltd.
- 473 Manzano-Salgado CB, Casas M, Lopez-Espinosa M-J, Ballester F, Basterrechea M, Grimalt JO, Jiménez A-M,
474 Kraus T, Schettgen T, Sunyer J, et al. Transfer of perfluoroalkyl substances from mother to fetus in a
475 Spanish birth cohort. *Environ Res* [Internet] 2015;142:471–478. Elsevier.
- 476 Monroy R, Morrison K, Teo K, Atkinson S, Kubwabo C, Stewart B, Foster WG. Serum levels of perfluoroalkyl
477 compounds in human maternal and umbilical cord blood samples. *Environ Res* 2008;108:56–62.
- 478 Mund M, Louwen F, Klingelhoefer D, Gerber A. Smoking and pregnancy--a review on the first major
479 environmental risk factor of the unborn. *Int J Environ Res Public Health* [Internet] 2013;10:6485–6499.
- 480 Okada E, Kashino I, Matsuura H, Sasaki S, Miyashita C, Yamamoto J, Ikeno T, Ito YM, Matsumura T,
481 Tamakoshi A, et al. Temporal trends of perfluoroalkyl acids in plasma samples of pregnant women in
482 Hokkaido, Japan, 2003–2011. *Environ Int* 2013;60:89–96.
- 483 Okada E, Sasaki S, Kashino I, Matsuura H, Miyashita C, Kobayashi S, Itoh K, Ikeno T, Tamakoshi A, Kishi R.
484 Prenatal exposure to perfluoroalkyl acids and allergic diseases in early childhood. *Environ Int*
485 2014;65:127–134.
- 486 Olsen GW, Burris JM, Ehresman DJ, Froelich JW, Seacat AM, Butenhoff JL, Zobel LR. Half-life of serum
487 elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired
488 fluorochemical production workers. *Environ Health Perspect* 2007;115:1298–1305.
- 489 Olsen GW, Butenhoff JL, Zobel LR. Perfluoroalkyl chemicals and human fetal development: An
490 epidemiologic review with clinical and toxicological perspectives. *Reprod Toxicol* 2009;27:212–230.
- 491 Olsen GW, Hansen KJ, Stevenson LA, Burris JM, Mandel JH. Human donor liver and serum concentrations of
492 perfluorooctanesulfonate and other perfluorochemicals. *Environ Sci Technol* [Internet] 2003a;37:888–
493 891.
- 494 Olsen GW, Hansen KJ, Stevenson LA, Burris JM, Mandel JH. Human Donor Liver and Serum Concentrations
495 of Perfluorooctanesulfonate and Other Perfluorochemicals. *Environ Sci Technol* 2003b;37:888–891.
- 496 Olsen GW, Lange CC, Ellefson ME, Mair DC, Church TR, Goldberg CL, Herron RM, Medhdizadehkashi Z,
497 Nobiletti JB, Rios JA, et al. Temporal trends of perfluoroalkyl concentrations in American Red Cross
498 adult blood donors, 2000–2010. *Environ Sci Technol* [Internet] 2012;46:6330–6338.
- 499 Papadopoulou E, Haug LS, Sabaredzovic a, Eggesbo M, Longnecker MP. Reliability of perfluoroalkyl
500 substances in plasma of 100 women in two consecutive pregnancies. *Environ Res* [Internet]
501 2015;140:421–429. Elsevier.
- 502 Pérez F, Nadal M, Navarro-Ortega A, Fàbrega F, Domingo JL, Barceló D, Farré M. Accumulation of
503 perfluoroalkyl substances in human tissues. *Environ Int* 2013;59:354–362.
- 504 Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL. Subchronic toxicity studies on
505 perfluorooctanesulfonate potassium salt in cynomolgus monkeys. *Toxicol Sci* 2002;68:249–264.
- 506 Solla SR De, Silva AO De, Letcher RJ. Highly elevated levels of perfluorooctane sulfonate and other
507 perfluorinated acids found in biota and surface water downstream of an international airport,
508 Hamilton, Ontario, Canada. *Environ Int* [Internet] 2012;39:19–26. Elsevier B.V.
- 509 Wang Y, Adgent M, Su P-H, Chen H-Y, Chen P-C, Hsiung CA, Wang S-L. Prenatal Exposure to
510 Perfluorocarboxylic Acids (PFCAs) and Fetal and Postnatal Growth in the Taiwan Maternal and Infant
511 Cohort Study. *Environ Health Perspect* [Internet] 2016;124:.

- 512 Yu W-G, Liu W, Jin Y-H, Liu X-H, Wang F-Q, Liu L, Nakayama SF. Prenatal and postnatal impact of
513 perfluorooctane sulfonate (PFOS) on rat development: a cross-foster study on chemical burden and
514 thyroid hormone system. *Environ Sci Technol* [Internet] 2009;43:8416–8422.
- 515 Zhang Y, Beesoon S, Zhu L, Martin JW. Biomonitoring of Perfluoroalkyl Acids in Human Urine and Estimates
516 of Biological Half-Life. *Environ Sci Technol* [Internet] 2013;47:10619–10627.
- 517 Zhou W-L, Medine CN, Zhu L, Hay DC. Stem cell differentiation and human liver disease. *World J
518 Gastroenterol* [Internet] 2012;18:2018–2025.
- 519
- 520 **Figure Legends:**
- 521
- 522 **Figure 1.** Study population, plasma and placenta samples, and fetuses included.
- 523 **Figure 2.** Concentrations of cotinine and PFASs in maternal plasma (A) and in placenta and different fetal
524 organs (B). Error bars represent min. and max. values. Maternal plasma cotinine (n=14); Cotinine NS: non-
525 smokers; S: Smokers; CT: Connective tissue.*Cotinine concentrations in fetuses exposed to maternal
526 cigarette smoke (n=21).
- 527 **Figure 3.** Mean concentration of PFOS and PFNA per fetus in relation to fetal age in days post conception
528 (pc). Solid lines are unadjusted regression lines, dotted lines are error bars. A significant positive correlation
529 between fetal age and PFOS and PFNA were found.
- 530 **Figure 4.** Concentration of PFNA and PFUnDA in maternal plasma in relation to maternal body mass index
531 (BMI). Solid lines are unadjusted regression lines, dotted lines are error bars. A significant positive
532 correlation between fetal age and PFOS and PFNA were found.

533

534

535